Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model

Bioluminescence imaging has previously been used to monitor the formation of grafted tumors in vivo and measure cell number during tumor progression and response to therapy. The development and optimization of successful cancer therapy strategies may well require detailed and specific assessment of biological processes in response to mechanistic intervention. Here, we use bioluminescence imaging to monitor the cell cycle in a genetically engineered, histologically accurate model of glioma in vivo. In these platelet-derived growth factor (PDGF)-driven oligodendrogliomas, G1 cell-cycle arrest is generated by blockade of either the PDGF receptor or mTOR using small-molecule inhibitors.

[1]  E. Hafen,et al.  Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. , 2003, Molecular cell.

[2]  J. Blenis,et al.  An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[4]  Peter Choyke,et al.  Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. , 2003, BioTechniques.

[5]  David K. Stevenson,et al.  Bioluminescent indicators in living mammals , 1998, Nature Medicine.

[6]  N. Socci,et al.  Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. , 2003, Molecular cell.

[7]  Daniel E. Hall,et al.  Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. , 2000, Neoplasia.

[8]  Daniel E. Hall,et al.  Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. , 2002, Molecular imaging.

[9]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[10]  R. Blasberg,et al.  In vivo imaging of molecular-genetic targets for cancer therapy. , 2003, Cancer cell.

[11]  J. Nevins,et al.  Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. , 1994, Genes & development.

[12]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.

[13]  Eric C. Holland,et al.  Gliomagenesis: genetic alterations and mouse models , 2001, Nature Reviews Genetics.

[14]  R A Moats,et al.  Time course of bioluminescent signal in orthotopic and heterotopic brain tumors in nude mice. , 2003, BioTechniques.

[15]  P. Wen,et al.  Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector , 1997, Nature Medicine.

[16]  Ralph Weissleder,et al.  Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo , 2003, Oncogene.

[17]  G. Fuller,et al.  The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. , 2005, Neoplasia.

[18]  Masafumi Oshiro,et al.  Visualizing Gene Expression in Living Mammals Using a Bioluminescent Reporter , 1997, Photochemistry and photobiology.